Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Carcinoma, Renal Cell × Ipilimumab × Clear all

Phase

Phase 2 19 Phase 1 14 Phase 1/2 9 Phase 3 6 Phase NA 1 Phase EARLY_PHASE1 1 Phase 4 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 2 Melanoma 2 Skin Neoplasms 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Kidney Neoplasms 1 Carcinoma, Renal Cell 1

Interventions

Sunitinib 5 Everolimus 5 Nivolumab 4 pazopanib 3 cabozantinib 2 aldesleukin 2 palbociclib 1 olaparib 1 lenvatinib 1 Zoledronic Acid 1 Tobacco Use Cessation Devices 1 Standard of Care 1 Sorafenib 1 Single Person 1 Radiotherapy 1 Psychiatric Rehabilitation 1 Polymerase Chain Reaction 1 Nutrition Therapy 1 Midazolam 1 Ipilimumab 1 Interferons 1 High-Energy Shock Waves 1 Gene Expression Profiling 1 Gemcitabine 1 Erlotinib Hydrochloride 1 Early Intervention, Educational 1 Counseling 1 Caffeine 1 Bupropion 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02982954 2022-11-01

CHECKMATE 920

Bristol-Myers Squibb

Phase 4 Completed

211 enrolled 21 charts

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡